🇺🇸 FDA
Patent

US 12331124

ALK2 antibodies and methods of use thereof

granted A61KA61K2039/505A61P

Quick answer

US patent 12331124 (ALK2 antibodies and methods of use thereof) held by Keros Therapeutics, Inc. expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Keros Therapeutics, Inc.
Grant date
Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K2039/505, A61P, A61P19/00, A61P19/10